Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293059 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT00293059 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 190 participants.
The verdict
NCT00293059, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
Interventions
- DRUG Placebo
- DRUG Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293059
The ClinicalTrials.gov registry entry for NCT00293059 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00293059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293059 about?
NCT00293059 is a clinical study titled "Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding". The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
What is the current status of trial NCT00293059?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2005-12. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00293059?
The interventions under investigation include: Placebo (DRUG), Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) (DRUG).
Who is sponsoring clinical trial NCT00293059?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.